@nicogagelmann.bsky.social shares findings that longer telomeres in donors ≥35 are associated with reduced graft failure and lower non-relapse mortality following allogeneic HCT. #ASH25
Nico Gagelmann
@nicogagelmann.bsky.social
Hematologist. Academic. Train. Think. Let's create and integral and loving actuality.
Don't get left out at sea! Prepare now for ASH-a-Palooza at #ASH25🐬 ◽Sign up early for Blood Buddy speed mentoring: https://ow.ly/Cafw50XA6Gt ◽Arrive by 11:45 a.m. for the Global Hematology Trainee Networking Lunch ◽Join the AAP treasure hunt ( in the #ASH25 app) #ASHTrainee ASH Education
The #ASH25 virtual platform is now live! Log in now using the ASH username and password you used to register for the annual meeting: https://ow.ly/MmlR50XBiMT 🌟Your bonus and preview content await. Plus, explore networking, exhibits, and more on the virtual platform! #HemeSky #MedSky
Your go-to social media guide for #ASH25 is here. Find tips on following updates, taking part in conversations, using the official hashtags, and entering fun challenges with #ASHNewsDaily. Read now: https://ow.ly/tEgJ50XxAP6 #HemeSky #ASHaiku #ASHKudos #ASHRunWalk #ASHScavengerHunt
The ASH annual meeting is the premier venue for #hematology collaborations across borders 🌏 #ASHThrowback to a meeting with ASH and the Mediterranean Partner Societies at #ASH24. Belinda Avalos, MD #ASH25 International community, share your throwbacks from past ASH meetings! #HemeSky
Finally in Boston! Honored to join @danafarber.bsky.social, eager to learn and contribute in this terrific community @coleman-lindsley.bsky.social. A place of science, purpose and hope.
Thank you all who made COSTEM 2025 THE event for transplant & cellular therapies❗️ Faculty who fight REAL debates Audience that ask REAL questions Unity amid controversy🙏 See you 1-3 October 2026 in Berlin again!
Last Call for Early Bird Registration Join us at the 10th COSTEM Congress! 🗓️ September 25–28, 2025 📍 Berlin, Germany Don't miss your chance to save – Early Bird registration closes July 31st! costem.cme-congresses.com/registration/
Registration - COSTEM Congress 2025
Registration for COSTEM 2025
costem.cme-congresses.com
🎥 Check out our recent interview from #CART25 with @nicogagelmann.bsky.social, in which he highlights the need to address inequality & inequity in access to #CARTCell therapy across Europe: 👉 buff.ly/4gBhWeD #ImmunoOnc #HemOnc #Hematology #MedSky #BloodSky #HemeSky
Out now in Blood Advances 🙌🏽 Our work from Princess Margaret Cancer Centre evaluating the role of PTCy in matched sibling donor allogeneic transplantation! Also read this excellent commentary by my good friend @nicogagelmann.bsky.social 👇🏽 ashpublications.org/bloodadvance...
MAKE CAR-T AFFORDABLE AGAIN Terrific learning experience from cellular therapy programs in India, Slovenia, Brazil and Turkey #CART25
Let's learn hematology in 2025🩸 Day 27: hemophilia characteristics
🎉Finally published🎉 Cilta-cel vs ide-cel for relapsed or refractory multiple myeloma @hemasphere-journal.bsky.social onlinelibrary.wiley.com/doi/full/10....
Idecabtagene vicleucel or ciltacabtagene autoleucel for relapsed or refractory multiple myeloma: An international multicenter study
Idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel) have revolutionized the treatment of relapsed/refractory multiple myeloma (RRMM), but direct comparisons are lacking. Levera...
onlinelibrary.wiley.com
🎉Finally published🎉 Clearance of driver mutations after transplantation for myelofibrosis @nejm.org www.nejm.org/doi/full/10....
Clearance of Driver Mutations after Transplantation for Myelofibrosis | NEJM
Allogeneic hematopoietic stem-cell transplantation is the only curative treatment for myelofibrosis. Driver mutations are the pathophysiological hallmark of the disease, but the role of mutation cl...
nejm.org
In a single-group, single-center study, clearance of driver mutations 30 days after bone marrow transplantation predicted long-term disease-free survival in patients with myelofibrosis. Read the full study results: nej.md/4fQNdKn #MedSky
Clearance of Driver Mutations after Transplantation for Myelofibrosis | NEJM
Allogeneic hematopoietic stem-cell transplantation is the only curative treatment for myelofibrosis. Driver mutations are the pathophysiological hallmark of the disease, but the role of mutation cl...
nej.md
Talquetamab plus Teclistamab in Multiple Myeloma (RedirecTT-1 study) nej.md/4iZNYTY Driver Mutations in Myelofibrosis (single-group, single-center study) nej.md/4fQNdKn
a blockbuster paper by @nicogagelmann.bsky.social et al in @nejm.org on the impact of driver mutation clearance in patients with MF that underwent allo-HCT! www.nejm.org/doi/full/10....
🎉Finally published🎉 Clearance of driver mutations after transplantation for myelofibrosis @nejm.org www.nejm.org/doi/full/10....
Clearance of Driver Mutations after Transplantation for Myelofibrosis | NEJM
Allogeneic hematopoietic stem-cell transplantation is the only curative treatment for myelofibrosis. Driver mutations are the pathophysiological hallmark of the disease, but the role of mutation cl...
nejm.org
What a wonderful #ASH24 Honored to receive @ash-hematology.bsky.social Abstract Achievement Award, meet friends, celebrate colleagues' achievements, enjoy terrific science and San Diego. Until next year 🙏🩸❤️
Tomorrow @nicogagelmann.bsky.social will take over our Twitter account, bringing you live updates & expert takes straight from #ASH24 🗞️🩸📱 Give us a follow over there so you don't miss the action 👉 x.com/VJHemOnc 👀
Now @nicogagelmann.bsky.social on molecular genetics and JAKi impact on allo-HCT in MF -1800 rux treated pts -early allo in high-risk PMF and SMF seems to be best timing -early allo in TP53 may offer survival benefit
🎉Finally out and timely for #ASH24 @ash-hematology.bsky.social 🎉 Happy to share our international work suggesting bispecific antibodies as standard of care for relapse after CAR-T in multiple #myeloma #mmsm t.co/F7QjOoavKO
https://www.nature.com/articles/s41408-024-01197-2
t.co
Happy to present first European comparison of cilta-cel vs ide-cel for #myeloma #ASH24: -Cilta-cel with better ORR, CR, PFS -Similar NRM -Peak CAR-T expansion day 14 for cilta-cel vs day 7 for ide-cel 👉associated with response and with ICANS for cilta-cel @ash-hematology.bsky.social
Honored to be featured on the @ash-hematology.bsky.social ASH News Daily #ASH24 follow list! I'll be posting on both my Twitter (https://buff.ly/3Zy7BLc) and BS (https://buff.ly/3B9SpKU), so please do follow! https://buff.ly/49iWb1d
#ASH24 of the day: Talquetamab Bridging before CAR-T -Talq bridging: 62% ORR (14% CR) -Post-CAR-T: 97.5% ORR (35% CR) -Safety: Mild toxicities during talq (no grade ≥3 CRS, 2.5% ICANS) -Post-CAR-T: less CRS (65%), ICANS (2% grade 3) Should be standard of care #mmsm @ash-hematology.bsky.social